Mario Tama
Johnson & Johnson’s (NYSE:JNJ) BioSense Webster unit said that it has received FDA approval for several of its cardiac ablation products for use in workflow without fluoroscopy.
J&J said the approval covers the Thermocool Smarttouch SF catheter, Carto Vizigo Bi-Directional Guiding Sheath, Pentaray Nav Eco High Density Mapping Catheter, Decanav Mapping Catheters and Webster CS Catheter. The devices are used for cardiac ablation procedures to treat atrial fibrillation, a common type of irregular heartbeat.
The company said the updated workflow indicates that direct imaging guidance, such as ultrasound, can be used as an alternative to fluoroscopy, which carries certain radiation exposure risks.
Biosense Webster is a division of Johnson & Johnson MedTech.
Last month, J&J reported better-than-expected earnings, thanks in part to strong sales of its medtech products.
More on J&J:
J&J falls after bankruptcy plan rejected for second time
